We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
bluebird bio Stock Up on Start of Phase III LentiGlobin Study
Read MoreHide Full Article
bluebird bio, Inc. (BLUE - Free Report) announced the commencement of a phase III study on its experimental gene therapy, LentiGlobin, which will incorporate an improved manufacturing process to increase transduction efficiency in patients with transfusion-dependent beta-thalassemia, a rare blood disorder.
Shares of the biotech company were up almost 9% yesterday on the news.
HGB-207, a global, multi-center study, will comprise the addition of bluebird bio’s transduction enhancers to the hematopoietic stem cell (HSC) manufacturing process. The company believes that adding transduction enhancers to the manufacturing process will lead to a substantial increase in hemoglobin levels in patients and reduce their transfusion requirements.
The primary endpoint of the study is to see whether patients on LentiGlobin, in combination with transduction enhancers, can achieve a 12-month transfusion-free period after transplant.
LentiGlobin has been granted Breakthrough Therapy status in the U.S. for the treatment of transfusion-dependent patients suffering from beta-thalassemia major.
bluebird bio also aims to incorporate these transduction enhancers into the manufacturing process for its another clinical trial, HGB-206, in the treatment of patients with severe sickle cell disease (SCD).
HGB-207 will primarily be conducted in the US. and is confirmatory in the EU.
bluebird bio has another candidate in its pipeline – Lenti-D, which is being studied in a phase II/III study (Starbeam Study) for the treatment of childhood cerebral adrenoleukodystrophy. We expect investor focus to remain on further pipeline updates from the company.
bluebird bio currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in medical genetics sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and Cambrex Corporation . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
bluebird bio Stock Up on Start of Phase III LentiGlobin Study
bluebird bio, Inc. (BLUE - Free Report) announced the commencement of a phase III study on its experimental gene therapy, LentiGlobin, which will incorporate an improved manufacturing process to increase transduction efficiency in patients with transfusion-dependent beta-thalassemia, a rare blood disorder.
Shares of the biotech company were up almost 9% yesterday on the news.
HGB-207, a global, multi-center study, will comprise the addition of bluebird bio’s transduction enhancers to the hematopoietic stem cell (HSC) manufacturing process. The company believes that adding transduction enhancers to the manufacturing process will lead to a substantial increase in hemoglobin levels in patients and reduce their transfusion requirements.
The primary endpoint of the study is to see whether patients on LentiGlobin, in combination with transduction enhancers, can achieve a 12-month transfusion-free period after transplant.
LentiGlobin has been granted Breakthrough Therapy status in the U.S. for the treatment of transfusion-dependent patients suffering from beta-thalassemia major.
bluebird bio also aims to incorporate these transduction enhancers into the manufacturing process for its another clinical trial, HGB-206, in the treatment of patients with severe sickle cell disease (SCD).
HGB-207 will primarily be conducted in the US. and is confirmatory in the EU.
bluebird bio has another candidate in its pipeline – Lenti-D, which is being studied in a phase II/III study (Starbeam Study) for the treatment of childhood cerebral adrenoleukodystrophy. We expect investor focus to remain on further pipeline updates from the company.
BLUEBIRD BIO Price
BLUEBIRD BIO Price | BLUEBIRD BIO Quote
Zacks Rank & Key Picks
bluebird bio currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in medical genetics sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and Cambrex Corporation . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>